SK6482000A3 - The use of a non-uterotrophic anti-estrogen and a progestin - Google Patents

The use of a non-uterotrophic anti-estrogen and a progestin Download PDF

Info

Publication number
SK6482000A3
SK6482000A3 SK648-2000A SK6482000A SK6482000A3 SK 6482000 A3 SK6482000 A3 SK 6482000A3 SK 6482000 A SK6482000 A SK 6482000A SK 6482000 A3 SK6482000 A3 SK 6482000A3
Authority
SK
Slovakia
Prior art keywords
ethoxy
benzyl
methyl
acceptable salt
pharmaceutically acceptable
Prior art date
Application number
SK648-2000A
Other languages
English (en)
Slovak (sk)
Inventor
Michael Jay Gast
Christopher Paul Miller
Original Assignee
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Prod filed Critical American Home Prod
Publication of SK6482000A3 publication Critical patent/SK6482000A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK648-2000A 1997-11-06 1998-11-04 The use of a non-uterotrophic anti-estrogen and a progestin SK6482000A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US96508397A 1997-11-06 1997-11-06
PCT/US1998/023427 WO1999024027A2 (en) 1997-11-06 1998-11-04 Anti-estrogen plus progestin containing oral contraceptives

Publications (1)

Publication Number Publication Date
SK6482000A3 true SK6482000A3 (en) 2000-11-07

Family

ID=25509417

Family Applications (1)

Application Number Title Priority Date Filing Date
SK648-2000A SK6482000A3 (en) 1997-11-06 1998-11-04 The use of a non-uterotrophic anti-estrogen and a progestin

Country Status (28)

Country Link
EP (1) EP1051179B1 (xx)
JP (1) JP2001522798A (xx)
CN (1) CN1278732A (xx)
AR (1) AR016667A1 (xx)
AT (1) ATE304359T1 (xx)
AU (2) AU760540B2 (xx)
BG (1) BG104451A (xx)
BR (1) BR9813982A (xx)
CA (1) CA2307210A1 (xx)
CZ (1) CZ294155B6 (xx)
DE (1) DE69831605T2 (xx)
DK (1) DK1051179T3 (xx)
EA (1) EA200000492A1 (xx)
EE (1) EE04092B1 (xx)
ES (1) ES2246541T3 (xx)
GE (1) GEP20043290B (xx)
HR (1) HRP20000269A2 (xx)
HU (1) HUP0100293A3 (xx)
ID (1) ID24568A (xx)
IL (1) IL135621A0 (xx)
NO (1) NO20002167L (xx)
NZ (1) NZ503890A (xx)
PL (1) PL340623A1 (xx)
SK (1) SK6482000A3 (xx)
TR (1) TR200001268T2 (xx)
UA (1) UA68365C2 (xx)
WO (1) WO1999024027A2 (xx)
ZA (1) ZA9810136B (xx)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL120263A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to prevent bone loss-progesterone and estrogen agonists
DE69909616T2 (de) * 1998-05-15 2004-06-17 Wyeth 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indol und estrogen als kombinationpräparate
US6479535B1 (en) 1998-05-15 2002-11-12 Wyeth 2-phenyl-1-[4-(2-aminoethoxy)-benzyl]-indole and estrogen formulations
AU764436B2 (en) * 1999-09-13 2003-08-21 Wyeth Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-1-(4-(2- amin-yl-ethoxy)-benzyl)-1H-indol-5-ols
US6380166B1 (en) 1999-09-13 2002-04-30 American Home Products Corporation Glucopyranosides conjugates of 2-(4-hydroxy-phenyl)-3-methyl-1-[4-(2-amin-1-yl-ethoxy)-benzyl]-1H-indol-5-ols
US6376486B1 (en) 2000-07-06 2002-04-23 American Home Products Corporation Methods of inhibiting sphincter incontinence
CN1599606A (zh) 2001-07-31 2005-03-23 辉瑞产品公司 包含雌激素激动剂/拮抗剂、雌激素与孕激素组合的药物组合物、试剂盒和方法
AU2005302706B2 (en) 2004-10-27 2011-12-15 Janssen Pharmaceutica N.V. Indole derivatives useful as progesterone receptor modulators
FR2880625B1 (fr) * 2005-01-07 2007-03-09 Sanofi Aventis Sa Derives de n-(heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique
UY29527A1 (es) * 2005-05-13 2006-12-29 Schering Ag Composicinn farmaccutica que contienen gestrgenos y/o estrngenos y 5-metil - (6s) - tetrhidrofolato.
DE102008057230A1 (de) * 2008-11-11 2010-05-12 Bayer Schering Pharma Aktiengesellschaft Synergistische pharmazeutische Kombination mit einem Estrogenrezeptorantagonisten und einem Progestin
CA2800673A1 (en) 2010-06-10 2011-12-15 Aragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
CA2857057A1 (en) 2011-12-14 2013-06-20 Seragon Pharmaceuticals, Inc. Fluorinated estrogen receptor modulators and uses thereof
JP6776348B2 (ja) 2015-10-01 2020-10-28 オレマ ファーマシューティカルズ インク． テトラヒドロ−１Ｈ−ピリド［３，４−ｂ］インドール抗エストロゲン薬物
AU2016366680B2 (en) 2015-12-09 2021-06-24 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective estrogen receptor downregulators
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197046A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. C3-carbon linked glutarimide degronimers for target protein degradation
AU2017290748A1 (en) 2016-07-01 2019-01-17 G1 Therapeutics, Inc. Pyrimidine-based antiproliferative agents
WO2018081168A2 (en) 2016-10-24 2018-05-03 The Board Of Trustees Of The University Of Illinois Benzothiophene-based selective mixed estrogen receptor downregulators
JP7229162B2 (ja) 2017-01-06 2023-02-27 ジー１ セラピューティクス， インコーポレイテッド 癌の治療に対する併用療法
CN110461853A (zh) 2017-02-10 2019-11-15 G1治疗公司 苯并噻吩雌激素受体调节剂
FI3645001T3 (fi) 2017-06-29 2024-09-25 G1 Therapeutics Inc Git38:n morfisia muotoja ja niiden valmistusmenetelmiä
CN113453679A (zh) 2018-12-20 2021-09-28 C4医药公司 靶向蛋白降解
AU2020405237A1 (en) 2019-12-20 2022-07-07 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of EGFR
BR112022017393A2 (pt) 2020-03-05 2022-10-18 C4 Therapeutics Inc Composto, composição farmacêutica, método para tratar um transtorno mediado por brd9, e, uso de um composto
WO2024030968A1 (en) 2022-08-03 2024-02-08 Brystol-Myers Squibb Company Compounds for modulating ret protein
WO2024097980A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein inhibitors
WO2024097989A1 (en) 2022-11-04 2024-05-10 Bristol-Myers Squibb Company Ret-ldd protein degraders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA716118B (en) * 1970-10-05 1972-05-31 Richardson Merrell Inc Contraception
ZA9510926B (en) * 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
IL120263A0 (en) * 1996-02-28 1997-06-10 Pfizer Combination therapy to prevent bone loss-progesterone and estrogen agonists
DE69707189T2 (de) * 1996-04-19 2002-06-20 American Home Products Corp., Madison Östrogene Verbindungen
US5747480A (en) * 1996-05-08 1998-05-05 American Home Products Corporation Oral contraceptive

Also Published As

Publication number Publication date
EE200000211A (et) 2001-04-16
IL135621A0 (en) 2001-05-20
AU760540B2 (en) 2003-05-15
NZ503890A (en) 2002-08-28
CZ20001661A3 (cs) 2000-12-13
NO20002167D0 (no) 2000-04-27
HRP20000269A2 (en) 2000-12-31
PL340623A1 (en) 2001-02-12
AR016667A1 (es) 2001-07-25
EA200000492A1 (ru) 2000-10-30
NO20002167L (no) 2000-06-28
CZ294155B6 (cs) 2004-10-13
BR9813982A (pt) 2000-09-26
ID24568A (id) 2000-07-27
CA2307210A1 (en) 1999-05-20
WO1999024027A2 (en) 1999-05-20
ZA9810136B (en) 2000-05-05
DE69831605D1 (de) 2005-10-20
WO1999024027A3 (en) 1999-07-15
ES2246541T3 (es) 2006-02-16
EE04092B1 (et) 2003-08-15
EP1051179A2 (en) 2000-11-15
UA68365C2 (en) 2004-08-16
CN1278732A (zh) 2001-01-03
AU2003204896B2 (en) 2006-06-15
HUP0100293A2 (hu) 2001-10-28
AU1303199A (en) 1999-05-31
GEP20043290B (en) 2004-07-26
ATE304359T1 (de) 2005-09-15
DE69831605T2 (de) 2006-06-14
TR200001268T2 (tr) 2001-01-22
BG104451A (en) 2000-12-29
DK1051179T3 (da) 2005-10-31
EP1051179B1 (en) 2005-09-14
HUP0100293A3 (en) 2002-12-28
JP2001522798A (ja) 2001-11-20

Similar Documents

Publication Publication Date Title
SK6482000A3 (en) The use of a non-uterotrophic anti-estrogen and a progestin
US6326392B1 (en) Anti-estrogen plus progestin containing oral contraceptives
RU2245713C2 (ru) Прерывистая гормонозаместительная терапия низкими дозами эстрогена
FI103951B (fi) Ehkäisyjärjestelmä
KR101812160B1 (ko) 연장된 호르몬성 피임제 투약법에서 파탄성 출혈의 관리
BG62384B1 (bg) Прогестероново-антагонистични и антиестрогенови активнисъединения с общо приложение за женски контрацептиви
PH26709A (en) Compositions and method of selecting contraceptions
Morris et al. Fulvestrant ('Faslodex')--a new treatment option for patients progressing on prior endocrine therapy.
HU221169B1 (en) Use of estrogen and antiprogestin for producing pharmaceutical compositions useful in hormon replacement therapy and kit containing the same
MXPA06013418A (es) Composiciones y metodos para el tratamiento del trastorno disforico premenstrual.
CA2255863A1 (en) Progestogen-anti-progestogen regimens
WO2002004418A2 (en) Methods of inhibiting uterotrophic effects of estrogenic agents
JPH07215858A (ja) 機能障害性子宮出血を抑制する方法
US7256185B1 (en) Control of selective estrogen receptor modulators
US20030181431A1 (en) Control of selective estrogen receptor modulators
US20090023693A1 (en) New drospirenone/17beta-estradiol regimen, pharmaceutical combination product and kit for performing this regimen
RU2215540C2 (ru) Схемы приема гестаген-антигестагена
KR20010031801A (ko) 항에스트로젠과 프로제스틴을 함유하는 경구 피임제
EP1287817A1 (en) Method of treating uterine leiomyomas and intravaginal drug delivery vehicle for use in such method
MXPA97004742A (es) Compuestos con propiedades antagonistas de progesterona y anti-estrogeno para su uso combinado en la anticoncepcion femenina
US20080280861A1 (en) Method of Female Contraception and a Kit For Use Therein
CA2371635A1 (en) Use of antiprogestagens in combined therapy